Multiple Myeloma Clinical Trial
Official title:
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
The purpose of this phase II study is to assess the toxicity and efficacy of sequentially administered high dose chemotherapy followed by autologous stem cell rescue in the treatment of multiple myeloma. Prior studies have shown that dose-intensified melphalan can produce higher response rates and complete remission in some patients. Over the past several years, multiple phase II studies utilizing high dose chemotherapy or high dose chemo-radiotherapy with autologous marrow or peripheral blood stem cell rescue have demonstrated improved response rates and survival rates compared to historical controls. Recently a prospective randomized trial has demonstrated improved response rates, response duration and overall survival utilizing high dose therapy with autologous bone marrow support compared to standard chemotherapy. The primary cause of failure is relapse and it is unclear how many, if any, patients are cured by this approach. Based on observations of efficacy in Hodgkin's Disease, Non-Hodgkin's Lymphoma, and breast cancer, an approach utilizing sequential high dose chemotherapy in multiple myeloma was developed. This protocol tests the sequential regimen in multiple myeloma patients who have responded to a standard dose chemotherapy regimen prior to enrollment.
The purpose of this phase II study is to assess the toxicity and efficacy of sequentially
administered high dose chemotherapy followed by autologous stem cell rescue in the treatment
of multiple myeloma. Multiple myeloma is a chemotherapy sensitive disease but is not
curative with standard therapy with a median survival of 2 to 4 years. Prior studies have
shown that dose-intensified melphalan can produce higher response rates and complete
remission in some patients. Over the past several years, multiple phase II studies utilizing
high dose chemotherapy or high dose chemo-radiotherapy with autologous marrow or peripheral
blood stem cell rescue have demonstrated improved response rates and survival rates compared
to historical controls. Recently a prospective randomized trial has demonstrated improved
response rates, response duration and overall survival utilizing high dose therapy with
autologous bone marrow support compared to standard chemotherapy. The primary cause of
failure is relapse and it is unclear how many, if any, patients are cured by this approach.
Based on observations of efficacy in Hodgkin's Disease, Non-Hodgkin's Lymphoma, and breast
cancer, an approach utilizing sequential high dose chemotherapy in multiple myeloma was
developed. This protocol tests the sequential regimen in multiple myeloma patients who have
responded to a standard dose chemotherapy regimen prior to enrollment. As originally
written, eligible patients were required to have sensitive disease.
The protocol was revised in August 1998 to allow entry of patients with newly diagnosed
myeloma who had stable but not progressive disease following VAD chemotherapy. Patients with
recurrent myeloma were still required to have chemotherapy sensitive disease. Eligible
patients must also have pathologically confirmed multiple myeloma, no prior bone marrow
transplantation and acceptable organ function (pulmonary, renal, hepatic, and cardiac). The
recent revision of the protocol also allows entry of patients with renal insufficiency due
to multiple myeloma to be enrolled on the protocol. Prior to initiating high dose therapy,
patients must undergo a complete history and physical exam with routine lab work plus titers
for HIV, CMV, HSV, and VCV: immunoglobulin levels, beta-2 microglobulin and serum protein
electrophoresis as well as immunoelectrophoresis and bone marrow aspirates and biopsies.
These studies are all standard for multiple myeloma patients. All patients require a double
Human Hickman to be placed prior to the start of therapy. The protocol was originally
written to include total body irradiation and high dose Melphalan as a preparative regimen
for patients who had not received prior radiotherapy. Patients who were not eligible for TBI
received high dose BCNU plus Melphalan. A revision removed the TBI Melphalan arm from the
protocol after analysis of over 100 patients treated at Stanford University Medical Center
on this same protocol showed no difference in event-free survival or overall survival
between the TBI containing arm and the chemotherapy only preparative regimen. The TBI arm
was dropped due to the increased cost and morbidity of TBI and the associated scheduling and
logistics problems. The other revision to the protocol was the inclusion of CD34 stem cell
selection on the stem cells collected by leukapheresis following high dose cyclophosphamide.
This change was based on the results of a Phase III study which demonstrated that the degree
of tumor cell contamination of these stem cell collections could be decreased by 3-6 logs
with CD34 cell selection. The dose of Melphalan was also increased to 200 mg/m2 after
completion of a dose escalation study at Stanford.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |